SFGate

Biotech firm Fluidigm withdraws IPO

Fluidigm Corp. is ending its effort to go public because turbulence in the financial markets made it impossible to complete the offering, the company said Thursday. The small South San Francisco ...
Business Insider

Fluidigm Drives a New Standard in Human Immune Profiling

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced it has exceeded $1 million in revenue from its industry-leading Maxpar® Direct™ Immune ...
Business Insider

Fluidigm to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...
Nasdaq

Reflecting on Fluidigm's (NASDAQ:FLDM) Share Price Returns Over The Last Five Years

Fluidigm Corporation (NASDAQ:FLDM) shareholders should be happy to see the share price up 17% in the last quarter. But if you look at the last five years the returns have not been good. You would have ...
GEN

Oncomed to Exploit Fluidigm’s Microfluidic Devices in Cancer Stem Cell Research

Collaboration will perform gene-expression analysis of tumors and evaluate changes in cancer stem cells when mAbs are used. OncoMed Pharmaceuticals is tapping Fluidigm’s microfluidic tools for the ...
CNN

University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...